RFI Novel Antimalarial Drug Targets

Closed Pre-Solicitation Posted

Not the latest version. See the latest special notice from .

Solicitation number
PANDHA-25-P-0000-015601-RFI-Novel-Antimalarial-Drug-Targets
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Place of performance
United States

Notice details come from SAM.gov. Updated .

About this opportunity

The Defense Health Agency, specifically the Walter Reed Army Institute of Research (WRAIR), Center for Infectious Disease Research (CIDR), and Viral Diseases Branch (VDB), is conducting a Request for Information (RFI) for a non-commercial research and development project focused on novel antimalarial drug targets. The two-year contract seeks a contractor with advanced chemistry and biotechnology capabilities to investigate the Structure-Activity Relationship (SAR) of compound WR936909 through complex research methodologies. Key requirements include synthesizing WR936909 and its structural analogs, designing and synthesizing conjugated affinity probes, performing proteomic analysis using Liquid Chromatography-Tandem Mass Spectrometry, and evaluating Plasmodium stage-specific protein expression. The RFI is primarily seeking capability statements and fact sheets from potential contractors, with responses due by May 19, 2025, at 2 pm EST. Contractors must have expertise in biotechnology research and be able to perform work at facilities located within the Continental United States.

The contract opportunity is not designated with any specific set-aside and falls under NAICS code 541714 for Research and Development in Biotechnology. The anticipated period of performance is precisely two years, commencing on September 30, 2025, and concluding on September 29, 2027. While specific award values are not disclosed in the documentation, the project will require substantial laboratory resources, including materials, supplies, chemicals, reagents, and analytical support. The contractor will be responsible for providing all necessary resources to conduct the research, with work to be performed off-site at the contractor's facilities. The primary research objective is to explore and understand the mechanisms and potential of compound WR936909 in antimalarial drug development, indicating a sophisticated and targeted scientific investigation with potential significant implications for infectious disease treatment.

Notice text

This Request for Information (RFI)/Sources Sought (SS) Notice is for market research information and planning purposes only, and shall not be construed as a solicitation or as an obligation on the part of WRAIR, CIDR, VDB, or the Defense Health Agency (DHA) US Army Medical Research Acquisition Activity (USAMRAA).  

This non-commercial R&D requirement is expected to be a two-year study with a straight two-year Period of Performance (PoP) beginning September 30, 2025, and ending September 29, 2027.

The work to be performed under this contract shall be performed off-site at Contractor facilities that may be located anywhere in the Continental United States (CONUS).

See attached Request for information With DRAFT Statement of Work. 

Files

File Type Posted
A03 Request for Information.pdf PDF

Notice history

Notice Type Posted
Novel Antimalarial Drug Targets Latest special notice Special Notice
This notice Original Pre-Solicitation

Similar open opportunities

Opportunity Agency Set-aside Responses due
Reqeust for Information (RFI) Consumables and Reagents BPA - WRAIR Africa Nairobi Kenya · NAICS 339112 — No set-aside
Request for Information – Prophylactic Platform for Medical Countermeasures Frederick, Maryland 21702, United States · NAICS 541715 ACC Aberdeen Proving Ground No set-aside
2027 NIAID DMID Omnibus Broad Agency Announcement: Development of Medical Interventions for Infectious Diseases NAICS 541715 National Institute of Allergy and Infectious Diseases No set-aside

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors